ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study

Bristol Myers Squibb may have gone big in its pursuit of cereblon E3 ligase modulator (CELMoD) drugs, but today the pharma is standing tall.